FDA 483 - Susan Seedman, M.D. - August 30, 2024

An FDA inspection of Susan Seedman, M.D. in Rio Rancho, NM, revealed significant deficiencies in clinical trial conduct. Observations included failures to adhere to investigational plans, specifically regarding subject eligibility and timely reporting of serious adverse events. Additionally, informed consent documents lacked crucial information about compensation for research-related injuries.